MeMed: Frédéric Sweeney
Frédéric Sweeney has joined MeMed as its chief business development officer. He will focus on building strategic partnerships to accelerate market access to the company's technologies, which include the MeMed BV, an immune system, blood-based test that distinguishes bacterial from viral infections, and the MeMed Key platform for measuring multiple proteins with central lab precision at the point of care within minutes. Sweeney was most recently entrepreneur-in-residence at Versant Ventures, and chief buisness officer at Northern Biologics. Prior to that, he was vice president of corporate development and head of strategic financing at BioMérieux. He was head of business development and strategy at T2 Biosystems before that.